Concepedia

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Juan P. Frías, Pernille Auerbach, Harpreet S. Bajaj, Yasushi Fukushima, Ildiko Lingvay, Stanislava Macura, ANETTE L. SØNDERGAARD, Tsvetalina Tankova, Nikolaοs Tentolouris, John B. Buse

The Lancet Diabetes & Endocrinology · 2021 · 176 citations · 19 references

DOI

Concepts

References

19

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al. · Annals of Internal Medicine · 2009 · 25.7K citations

, , +12

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies, David A. D’Alessio, Judith Fradkin et al. · Diabetes Care · 2018 · 3.5K citations · Full text

, , +17

9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2022</i>

Diabetes Care · 2021 · 1.5K citations

, , +13

6. Glycemic Targets: <i>Standards of Medical Care in Diabetes—2022</i>

Diabetes Care · 2021 · 1.4K citations · Full text

, , +15

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018 · 764 citations

, , +13